US5047228A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Nonionic 5-C-substituted 2,4,6-triiodoisophthalic acid derivatives
Assignee: Bayer Pharma AG
•
Filing: 1989-03-02
•
Granted: 1991-09-10
•
Expires: 2009-03-02
Abstract
Abstract Nonionic compounds of the formula ##STR1## wherein X is --CONR 1 R 2 , --COOR 3 , --CH 2 NHR 7 or --CH 2 OH; Y is --1R 1 R 2 or --OR 3 ; and Z is --NR 1 R 2 , --NHR 7 or --OR 3 ; and wherein R 1 R 2 and R 3 in X, Y or Z, and R 7 in X and Z, are identical or different, R 1 and R 2 , and each is hydrogen, C 1-6 -alkyl or C 2-8 - alkyl substituted by 1-5 OH groups and/or by a C 1-3 -alkoxy group; R 3 is C 1-4 -alkyl or C 2-4 -alkyl substituted by 1-2 OH groups and/or by a C 1-3 -alkoxy group; and R 7 is an acyl group of a C 2-5 OH group and/or by a C 1-3 -alkoxy group are highly advantageous X-ray contrast agents.
Inventors
- 👤 Heinz Gries
- 👤 Heinrich Pfeiffer
- 👤 Ulrich Speck
- 👤 Wolfgang Mutzel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 22:53
CPC Classifications
C; C07; C07C; C07C233/00; C07C233/64; C07C233/67; C07C233/68; C07C233/69
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
3 words
2,4,6-Triiodobenzene-1,3,5-tricarboxylic acid tris(2,3-dihydroxypropyl-N-methylamide).
Claim 2
Dependent Claim
3 words
2,4,6-Triiodobenzene-1,3,5-tricarboxylic acid tris(2,3-dihydroxypropyl-N-methylamide).
Claim 3
Dependent Claim
3 words
2,4,6-Triiodobenzene-1,3,5-tricarboxylic acid tris[bis(2-hydroxyethyl)]triamide.
Claim 4
Dependent Claim
3 words
2,4,6-Triiodobenzene-1,3,5-tricarboxylic acid tris[bis(2-hydroxyethyl)]triamide.
Claim 5
Dependent Claim
3 words
5-N-Methylcarbamoyl-2,4,6-triiodiosophthalic acid bis(2,3-dihydroxy-1-hydroxymethylpropyl)diamide.
Claim 6
Dependent Claim
3 words
5-N-Methylcarbamoyl-2,4,6-triiodiosophthalic acid bis(2,3-dihydroxy-1-hydroxymethylpropyl)diamide.
Claim 7
Dependent Claim
37 words
An X-ray contrast medium comprising an amount of a compound of claim 1 effective to make the medium opaque to X-rays after it has been administered to a host undergoing X-ray diagnosis, and a pharmaceutically acceptable carrier.
Claim 8
Dependent Claim
19 words
The X-ray contrast medium of claim 4 wherein the amount of opaque agent is 50-400 mg I/ml of medium.
Claim 9
Dependent Claim
56 words
A method of rendering an inner cavity of a host opaque to X-rays, comprising administering an X-ray contrast medium of claim 4 to the host in such a manner that it passes through the inner cavity and in such an amount that, when the medium reaches the inner cavity, it renders the cavity opaque to X-rays.
Claim 10
Dependent Claim
44 words
A method of conducting angiography, urography, lymphography, computer tomography, bronchography, gastrointestinal visualization, arthrography or myelography on a patient in need of the same which comprises first administering an X-ray contrast medium in accordance with claim 6 and then exposing the patient to diagnostic X-raying.
Claim 11
Dependent Claim
37 words
An X-ray contrast medium comprising an amount of a compound of claim 2 effective to make the medium opaque to X-rays after its has been administered to a host undergoing X-ray diagnosis, and a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
19 words
The X-ray contrast medium of claim 8, wherein the amount of opaque agent is 50-400 mg I/ml of medium.
Claim 13
Dependent Claim
56 words
A method of rendering an inner cavity of a host opaque to X-rays, comprising administering an X-ray contrast medium of claim 8 to the host in such a manner that it passes through the inner cavity and in such an amount that, when the medium reaches the inner cavity, it renders the cavity opaque to X-rays.
Claim 14
Dependent Claim
44 words
A method of conducting angiography, urography, lymphography, computer tomography, bronchography, gastrointestinal visualization, arthrography or myelography on a patient in need of the same which comprises first administering an X-ray contrast medium in accordance with claim 10 and then exposing the patient to diagnostic X-raying.
Claim 15
Dependent Claim
37 words
An X-ray contrast medium comprising an amount of a compound of claim 13 effective to make the medium opaque to X-rays after it has been administered to a host undergoing X-ray diagnosis, and a pharmaceutically acceptable carrier.
Claim 16
Dependent Claim
19 words
The X-ray contrast medium of claim 12, wherein the amount of opaque agent is 50-400 mg I/ml of medium.
Claim 17
Dependent Claim
56 words
A method of rendering an inner cavity of a host opaque to X-rays, comprising administering an X-ray contrast medium of claim 12 to the host in such a manner that it passes through the inner cavity and in such an amount that, when the medium reaches the inner cavity, it renders the cavity opaque to X-rays.
Claim 18
Dependent Claim
44 words
A method of conducting angiography, urography lymphography, computer tomography, bronchography, gastrointestinal visualization, arthrography, or myelography on a patient in need of the same which comprises first administering an X-ray contrast medium in accordance with claim 14 and then exposing the patient to diagnostic X-raying.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-09-09 | 1995-03-11 | 1995-09-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-09-09 | 1999-03-11 | 1999-09-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-09-09 | 2003-03-11 | 2003-09-10 | $7700.00 | Window Closed / Lapsed |